Biotech stocks can be among the riskiest investments on the market, but despite the tragic plunges, there are also companies that are able to successfully launch innovative drugs for unmet needs, adapt to a rapidly changing competitive landscape, and succeed over the long term.
What qualities should biotech investors be looking for? To help shed light on this topic, health-care bureau chief Max Macaluso discusses biotech investing with Charly Travers, associate advisor for Motley Fool Million Dollar Portfolio. In the following video, they discuss the reasons behind the success of two of Charly's favorite biotechs.
Charly Travers has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends BioMarin Pharmaceutical, Gilead Sciences, and Vertex Pharmaceuticals. It recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Wall Street Is Clueless on Facebook
Long-term investors should trust Mark Zuckerberg and applaud recent timeline changes.
When Will Self-Driving Cars Be on the Market?
This week, we talk about what the Consumer Electronics Show revealed about the progress toward autonomous vehicles, plus the latest on BP and GE.
Better Buy: Himax Technologies, Inc. vs. Cypress Semiconductor
A strong case can be made for both semiconductor upstarts, but one holds the edge as the better buy.